BridgeBio Pharma Inc [NASDAQ: BBIO] closed the trading session at $45.98 on 2025-07-09. The day’s price range saw the stock hit a low of $43.91, while the highest price level was $46.4299.
The stocks have a year to date performance of 78.49 percent and weekly performance of 7.48 percent. The stock has been moved at 63.51 percent over the last six months. The stock has performed 19.06 percent around the most recent 30 days and changed 49.92 percent over the most recent 3-months.
If compared to the average trading volume of 3.09M shares, BBIO reached to a volume of 4633505 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BridgeBio Pharma Inc [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $61.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for BridgeBio Pharma Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 09, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on June 17, 2025, representing the official price target for BridgeBio Pharma Inc stock. Previously, the target price had yet another raise to $50, while Redburn Atlantic analysts kept a Buy rating on BBIO stock.
BBIO stock trade performance evaluation
BridgeBio Pharma Inc [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.48. With this latest performance, BBIO shares gained by 19.06% in over the last four-week period, additionally plugging by 63.51% over the last 6 months – not to mention a rise of 67.57% in the past year of trading.
BridgeBio Pharma Inc [BBIO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc [BBIO] shares currently have an operating margin of -537.55% and a Gross Margin at 92.24%. BridgeBio Pharma Inc’s Net Margin is presently recorded at -524.25%.
Return on Equity for this stock declined to -77.18%, with Return on Assets sitting at -77.18%.
BridgeBio Pharma Inc [BBIO]: Institutional Ownership
There are presently around $98.14%, or 103.28% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31.06 million shares, which is approximately 16.5582%. VIKING GLOBAL INVESTORS LP, holding 25.12 million shares of the stock with an approximate value of $$636.31 million in BBIO stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$356.01 million in BBIO stock with ownership which is approximately 7.4924%.
